Form 4/A for VERA Vera Therapeutics, Inc.
Accepted 2023-02-17 00:00:00 ET · period of report 2023-02-06 · accession 0001209191-23-010583 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2023-02-17 | 2023-02-06 | VERA | Grant Sean | CFO | P - Purchase | $7.00 | +14.3K | 49.9K | +40% | +$100.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2023-02-06 | P | A | 14,285 | $7.00 | 49,933 | D | — | — | (F1) The reporting person's original Form 4 contained a typographical error on the transaction date. (F2) Shares purchased by the Reporting Person in the Issuer's follow-on offering, which closed on February 6, 2023. The purchase price is the offering price. (F3) Includes 380 shares acquired under the Issuer's Employee Stock Purchase Plan on September 13, 2022. |